Research programme: cancer therapeutics - Deargen
Alternative Names: DG-ONCO-T2; DG-ONCO-T3; DG-ONCO-T4Latest Information Update: 16 Mar 2022
At a glance
- Originator Deargen
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 03 Mar 2022 Early research in Cancer in South Korea (unspecified route) (Deargen pipeline, March 2022)